LRMR实时信号 | 通过Getagraph.com最大化利润

购买 107681 min ago

@ $11.62

发出时间: 15 Feb 2024 @ 02:41

回报率: -44.55%

上一信号: Feb 14 - 04:50

上一信号: 出售

回报率: 25.70 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform...

Stats
今日成交量	144 231
平均成交量	650 811
市值	410.87M
EPS	$0 ( 2024-03-12 )
下一个收益日期	( $-0.240 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.67
ATR14	$0.00900 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 205	Common Stock
2024-02-14	Thomas Frank E	Buy	2 000	Common Stock
2024-01-17	Shankar Gopi	Buy	135 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 20 937 267 \| Sell: 6 152 661

音量相关性

長: -0.29 (neutral)

短: -0.56 (weak negative)

Signal:(38.262) Neutral

Larimar Therapeutics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Larimar Therapeutics Inc 相关性 - 货币/商品

0.50
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.37
( neutral )

-0.53
( weak negative )

-0.24
( neutral )

Larimar Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-311 000 (0.00 %)
EPS:	$-0.840

FY	2023
营收:	$0
毛利润:	$-311 000 (0.00 %)
EPS:	$-0.840

FY	2022
营收:	$0
毛利润:	$-272 000 (0.00 %)
EPS:	$-1.330

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.26

Financial Reports:

No articles found.

Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.